Table 1.

Clinical characteristics of study patients

Characteristics	Repaglinide and clopidogrel group	Mitiglinide and clopidogrel group	Repaglinide group	p value
	(N = 15)	(N = 15)	(N = 15)
Age	75.6 ± 12.2	70.4 ± 11.5	76.1 ± 10.9	0.332*
Male (%)	10 (66.7%)	12 (80.0%)	10 (66.7%)	0.649***
BMI	23.6 ± 3.2	24.4 ± 2.9	23.2 ± 3.9	0.598*
HbA1c	9.3 ± 2.0	9.5 ± 2.0	9.7 ± 2.6	0.851*
Serum creatinine	0.84 ± 0.32	0.80 ± 0.16	0.76 ± 0.16	0.594*
Liver function (Grade 1 [CTCAE ver.4.0]: AST, ALT, or T-Bil)	4 (26.7%)	5 (33.3%)	3 (20.0%)	0.912**
Calorie intake (kcal)	1325.9 ± 283.3	1497.0 ± 247.5	1517.2 ± 168.7	0.065*
Concomitant agent use (oral hypoglycemic drugs, insulin, GLP-1 agonists, and/or agents which may enhance the hypoglycemic action of repaglinide or mitiglinide, other than the above)	10 (67.7%)	9 (60.0%)	9 (60.0%)	0.910***

Mean ± S.D., * One-way analysis of variance, ** Fisher’s exact test, *** Chi-square test